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Abstract Introduction: Magnesium plays a role in a large number of cellular metabolic reactions.
Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) transport
in the kidney.We designed this trial to investigate ifMg2+ serum levelmodificationsmay be related
with clinical response and outcome in advanced colorectal cancer patients during treatment with
cetuximab plus irinotecan.
Experimental Design:Sixty-eight heavily pretreatedmetastatic colorectal cancer patientswere
evaluated for Mg2+ serum levels at the following time points: before; 6 hours; and1, 7,14, 21, 50,
and 92 days after the start of treatment.
Results: Basal Mg2+ median levels were significantly decreased just 7 days after the first
anticancer infusion and progressively decreased from the 7th day onward, reaching the highest
significance at the last timepoint (P < 0.0001).Twenty-five patients showeda reduction inmedian
Mg2+ circulating levels of at least 20% within the 3rd week after the first infusion. Patients with
this reduction showed a response rate of 64.0% versus 25.6% in the nonreduced Mg2+ group.
Themedian time to progressionwas 6.0 versus 3.6months in the reducedMg2+ group and in that
without reduction, respectively (P < 0.0001). Overall survival was longer in patients with Mg2+
reduction than in those without (10.7 versus 8.9 months).
Conclusions: Our results confirm that cetuximab treatment may induce a reduction of Mg2+
circulating levels and offer the first evidence that Mg2+ reductionmay represent a new predictive
factor of efficacy in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
Magnesium (with Mg referring to the total elemental content
and Mg2+ to its ionized form) is a critical cofactor in many
enzymatic reactions important for physiologic functions, such
as nucleic acid metabolism, protein synthesis, and energy
production (1, 2) Moreover, it seems to play a role in tumor
biology such as in the regulation of oxidative stress (3),
carcinogenesis (4), tumor progression (5), and angiogenesis (6).
With regard to the regulation of cell proliferation, there is
convincing evidence that Mg deficiency induces growth arrest
by affecting the expression levels of cell cycle regulatory
proteins, including p27, p21, cyclins, and CDKs. At the same
time, Mg can regulate other steps of cell proliferation such as
protein synthesis, DNA duplication, and mitosis (4). Interest-
ingly, mitochondria have all the characteristics to be considered
as Mg stores, as they possess specific channels to take up Mg
from the cytosol. In this regard, there is a challenging
possibility that Mg participates not only in ATP synthesis but
also in the apoptotic pathway (2).
Plasma and cellular Mg2+ concentrations are both tightly
controlled, although regulation of its balance is poorly
understood at the cellular and molecular levels.
Mg2+ homeostasis is determined by intestinal absorption and
renal excretion; thus, the kidney plays a key role in Mg2+
handling.
Because epidermal growth factor receptor (EGFR; also known
as c-erb1 or HER1) is strongly expressed in the kidney,
particularly in the ascending limb of the loop of Henle where
70% of filtered magnesium is reabsorbed, EGFR blockade may
interfere with magnesium transport (7).
Very recently, Groenestege et al. defined EGF as an autocrine/
paracrine magnesiotropic hormone that regulates renal Mg2+
reabsorption by regulating the activity of the Mg2+-permeable
channel TRPM6 (transient receptor potential cation channel,
subfamily M, member 6). The authors identified a point
mutation in pro-EGF that disrupts sorting of the protein to the
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basolateral membrane of distal convoluted tubule cells in
kidney nephrons (8). As a consequence, inhibition of the EGFR
by anti-EGFR antibodies led to suppressed activity of TRPM6
and renal Mg2+ wasting.
Inhibition of the EGFR has become a key part in the
treatment of various cancer types, either as monotherapy or in
combination with chemotherapy (9, 10).
Cetuximab is a chimeric IgG1 monoclonal antibody that
binds to EGFR with high specificity and with a higher affinity
than epidermal growth factors, blocking ligand-induced phos-
phorylation of EGFR.
Clinical trials have shown that cetuximab is synergistic with
chemotherapy for patients with metastatic colorectal cancer.
As a result, cetuximab is now regarded as part of standard
treatment practice in this disease (9, 11).
A previous study reported that patients with colorectal cancer
treated with cetuximab may develop a Mg2+ wasting syndrome
with hypomagnesemia and inappropriate urinary excretion.
Because EGFR is strongly expressed in the kidney, particularly
in the ascending limb of the Henle’s loop where 70% of filtered
Mg2+ is readsorbed, it was suggested that cetuximab blockade of
EGFR could interfere with Mg2+ transport, leading to hypo-
magnesemia in most patients (12).
We aimed to assess the occurrence of magnesium serum
levels modifications in advanced colorectal cancer patients
treated with a weekly combination of cetuximab plus irinotecan
and to evaluate the existence of a correlation with clinical
response and outcome during treatment.
Materials andMethods
Study design and patients eligibility criteria. Patients were consid-
ered eligible for the study if they had a histologically confirmed
colorectal adenocarcinoma (resected or not) associated with distant
metastases (with or without local relapse). Magnesium circulating levels
were analyzed in a population of colorectal cancer patients receiving
cetuximab + irinotecan as third-line anticancer treatment and resistant
to oxaliplatin- and irinotecan-based chemotherapy.
We included in the study patients older than 18 years, affected by
stage IV and histologically confirmed colorectal adenocarcinoma.
Immunohistochemical evidence of EGFR expression measured semi-
quantitatively (>0 on a scale of 0, 1+, 2+, or 3+) in a single reference
laboratory (University Campus Bio-Medico, Rome, Italy) was required.
These measurements were performed and graded using a commercially
available kit (EGFRpharmDx; Dako Corporation) according to the
manufacturer’s instructions. Standard criteria for anticancer treatment
suitability for all patients were used. In particular, renal function was
evaluated and only patients within the reference range (serum
creatinine 0.8-1.44 mg/dL) were included.
Patients were considered ineligible for accrual when they had
reported fever (body temperature >38.0jC) during the last week before
study entry or had received any radiotherapy, chemotherapy, immu-
notherapy, or growth factors during the last 4 wk before study accrual.
Moreover, if patients received radiotherapy or growth factors during our
study, they were excluded from the final evaluation as well. Patients
recently (<1 wk) or simultaneously treated with chronic steroid–based
therapy and with acute or chronic infections or inflammatory diseases
were considered ineligible for the study. Malabsorption syndromes,
uncontrolled diabetes, genetic magnesium wasting syndromes (such
as, Gitelman and Bartter syndrome), drugs, and toxins intake (such as,
ethanol, loop diuretics, thiazide, cisplatin, cyclosporine) were also
established criteria for ineligibility.
Before being considered in this study, all patients had a documented
disease progression after two standard anticancer regimens: one
oxaliplatin-based chemotherapy regimen (capecitabine + oxaliplatin
or FOLFOX IV regimen as first line) and one irinotecan-based
chemotherapy (FOLFIRI regimen as second line) for at least 2 mo.
Informed consent was obtained from all the subjects enrolled in the
study.
Treatment plan. Cetuximab was given at a loading dose of
400 mg/m2, followed by weekly infusions of 250 mg/m2. Irinotecan
was administered weekly at the dose of 90 mg/m2. A histamine receptor
antagonist and atropine (0.25 mg) were given as premedication before
every infusion. No corticosteroids were routinely administered, and
those patients treated with steroids for any reason after the accrual were
excluded. A standard antiemetic drug was always given in the
premedication and in the following days according to the physician’s
judgment. All the patients were treated until disease progression or until
unacceptable toxic effects occurred.
Modifications to cetuximab dose were made only in cases of toxic
effects to the skin and to irinotecan dose in cases of hematologic or
nonhematologic toxic effects. Tumor response was evaluated every 8 wk
by the use of consistent imaging techniques (computed tomography or
magnetic resonance imaging). Assessment was done by the investigators
according to the Response Evaluation Criteria in Solid Tumors. Adverse
events were recorded according to the National Cancer Institute
Common Toxicity Criteria version 2.0.
Electrolyte evaluation. Venous blood was drawn just before the
beginning of the 1st day and 1, 21, 50, and 92 d after cetuximab +
irinotecan infusion. Samples were rapidly centrifuged for 10 min at
3,500 rpm and serum stored at -80jC until tested. Moreover, standard
hematologic variables, including renal function, were tested before
every single course.
Serum magnesium and calcium concentrations were measured at
baseline and at any time point referred by use of a colorimetric assay
(xylidyl blue and arsenazo III method, respectively) in the Konelab 30i
automatic analyzer (Dasit s.p.a.) in a single reference laboratory
(University Campus Bio-Medico, Rome, Italy). The reference values
and standard laboratory deviations for magnesium and calcium were as
follows: Mg2+ 1.9 to 2.5 mg/dL, SD 0.15; Ca2+ 8.1 to 10.4 mg/dL, SD
0.575. Serum calcium concentrations were corrected for hypoalbumi-
nemia. All patients have at the moment of the analysis all serum
magnesium measurements; therefore, none was excluded from the final
analysis.
Statistical analysis. Basal magnesium levels were compared with the
values observed at 1, 21, 50, and 92 d after the start of cetuximab plus
irinotecan treatment using Wilcoxon’s test for nonparametric-depen-
dent continuous variables. A linear regression model was used to
perform the correlation between magnesium and calcium levels and at
each time points.
The time to progression (TTP) analysis was calculated as the period
from the date of starting the treatment to the first observation of disease
progression or to death from any cause within 60 days after the start of
treatment or the most recent tumor assessment. The overall survival
(OS) time was calculated as the period from the date of starting
treatment until death from any cause or until the date of the last follow-
up, at which point data were censored. TTP and OS were both
determined by Kaplan-Meier product-limit method (13).
Stratified permutation tests were carried out to explore the
association between tumor response and acne-like rash and between
tumor response and magnesium modifications. Moreover, the differ-
ences in terms of TTP and OS according to the presence and severity of
acne-like rash and the presence of magnesium reduction were evaluated
by the log-rank test (14). The Cox proportional hazards model was
applied to the multivariate survival analysis (15).
Patients were stratified according to magnesium reduction into two
groups to perform the survival analysis and the correlation with clinical
response. In particular, we decided to stratify patients into those who
developed a reduction z20% or <20%. The cutoff point was decided
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after having calculated the median value of percentage magnesium
reduction. Moreover, to evaluate the correlation between acne skin rash
and survival and clinical response, we compared patients who
developed a grade 0-1 rash versus patients with a grade 2-3 rash. We
have made this decision after having calculated the median value of
rash grade in all the cohort, to separate the patients’ population into
two equivalent groups.
The cutoff point for survival data was July 2007; for safety data, the
cutoff point was March 2007. SPSS software (version 13.05, SPSS, Inc.)
was used for statistical analysis. A P value of <0.05 was considered to
indicate statistical significance.
Results
Sixty-eight consecutive patients (35 males, 33 females), ages
27 to 82 years (median age, 65 years), with advanced colorectal
cancer were included in the study. All patients matched all the
inclusion criteria. Patient characteristics are shown in Table 1.
Magnesium analysis. The median magnesium basal value
showed a statistically significant decrease just 7 days after the
start of cetuximab plus irinotecan anticancer treatment. This
effect enhanced during the following analyzed time points as
reported in Table 2. The lowest levels of magnesium were
achieved at the last time point (92 days after the first cetuximab
infusion), with a median value of 1.75 mmol/L versus 2.12
mmol/L when compared with the basal time (P < 0.0001).
At any of the programmed time points, 65 of 68 patients
showed a reduction of magnesium serum levels; 25 of them
showed at least 20% reduction with respect to the basal level.
Only 3 patients during any of the programmed time points
developed a hypomagnesemia G1 according to the Common
Toxicity Criteria (all of them at the last time point). No cases of
hypomagnesemia higher than G1 were recorded.
Significant correlation in a linear regression model was
noted, as expected, between basal calcium serum levels and
basal magnesium serum levels (b regression coefficient = 4.230;
P = 0.009). Calcium levels progressively decreased during
cetuximab-based therapy, maintaining the correlation at any
time points (data not shown). However, the calcium reduction
was not clinically significant and only one patient developed a
grade 1 hypocalcemia during anticancer treatment.
Correlation of response and survival with magnesium reduc-
tion. An early magnesium reduction of at least 20% respect to
the basal value (between the 1st and the 3rd week after the first
infusion) represents a significant predictive factor for response.
Those patients who developed a decrease of magnesium serum
levels within the 1st and 3rd weeks after the start of treatment
showed a higher response rate compared with patients who did
not show an equal reduction (64.0% versus 25.6% P = 0.004).
Moreover, TTP was higher in the patient group with reduced
magnesium than in the other group (6 months versus 3.9
months; P < 0.0001). Moreover, stratifying patient population
according to the rank of early magnesium reduction (V10%, 10-
20%, and z20%), we identified that the rank of magnesium
reduction may also represent a predictive factor for TTP, as
described in Table 3.
Hence, the early reduction of magnesium serum levels
represents a significant prognostic factor of OS. In fact, those
patients with a magnesium reduction z20% had a longer OS
than those without (10.7 versus 8.9 months; P = 0.021). These
results are shown Table 4 and in Figs. 1 and 2
Correlation of response and survival with rash. A correlation
between the presence and severity of the acne-like rash and
tumor response was shown. In particular, patients with a grade
3 rash showed a higher response rate (57.7%) versus those
patients with a grade 0, 1, and 2 (28.6%), with a statistically
significant difference (P = 0.033). Moreover, comparing
patients who developed a grade 3 acne-like rash with the
others, a statistically significant correlation was recorded
Table 1. Baseline characteristics of the patients
Patient characteristics No. patients (%)
Total number 68 (100%)
Male/female 35/33 (51.4%/48.5%)
Age (y)
Median 65
Range 27-82
Performance status
Median 1
Range 1-2
Primary tumor site
Colon 42
Rectum 26
No. metastatic sites
1 21 (30.8%)
2 25 (36.7%)
3+ 22 (32.3%)
Sites of metastases
Liver 31 (45.5%)
Lung 20 (29.4%)
Nodes 16 (23.5%)
Local 12 (17.6%)
Other 19 (27.9%)
Prior adjuvant therapy
None 23 (33.8%)
FU/LV 45 (66.1%)
First-line regimen
XELOX 41 (60.3%)
FOLFOX 27 (39.7%)
Second line regimen
FOLFIRI 68 (100%)
EGFR expression
Score 1 21 (30.8%)
Score 2 29 (42.6%)
Score 3 18 (26.4%)
Abbreviations: FU/LV 5-FluoroUracil and folinic acid; XELOX,
oxaliplatin and capecitubine; FOLFOX, oxaliplatin and 5-Fluororacil
(bolus and continuous infusion) plus folinic acid; FOLFIRI,
irinotecan and 5-Fluouracil (bolus and continuous infusion) plus
folinic acid.
Table 2. Magnesium modification at different time
points
Time points Median (95% CI) P
Basal levels 2.12 (2.03-2.22) —
6 h 2.10 (2.0226-2.21) 0.666
1 d 2.15 (2.06-2.24) 0.956
7 d 2.05 (1.93-2.74) 0.020
14 d 2.00 (1.91-2.12) 0.005
21 d 1.96 (1.84-2.03) 0.003
50 d 1.91 (1.73-2.04) 0.001
92 d 1.75 (1.57-1.87) <0.0001
Abbreviation: 95% CI, 95% confidence interval.
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between the acne-like rash and TTP: 6.00 (5.53-6.44) versus
4.01 (3.75-4.45), P = 0.002. No statistically significant
difference in terms of overall OS between the two groups was
identified. These data are summarized in Table 4 and are shown
in Figs. 1 and 2.
Multivariate analysis of survival. Performing a multivariate
analysis of TTP, the early magnesium reduction preserved the
statistical significance whereas the acne-like skin rash lost its
significance, even if the P value was borderline. In detail, the
calculated relative risk of progression in the group of patients
with a >20% early magnesium modification is 0.187
(95% confidence interval, 0.103-0.339) with a P value of
0.001. The relative risk of progression for the group of patients
with G3 skin rash was 0.501 (95% confidence interval, 0.311-
1.088) compared with patients without this reduction
(P = 0.090).
Discussion
We evaluated serum magnesium concentrations in patient
affected by metastatic colon cancer during EGFR-targeting
antibody therapy; as a second step, we investigated the
existence of a correlation with clinical response and outcome
during treatment. Magnesium circulating levels were assessed at
the basal level and at different time points until 92 days after
the start of treatment. It is noteworthy that magnesium plays a
key role in many physiologic functions, such as nucleic acid
metabolism, protein synthesis, and energy production (1, 2);
interestingly, it also seems to play a role in tumor biology
(16, 17).
Because EGFR is strongly expressed in the ascending limb of
the loop of Henle, EGFR blockade may interfere with
magnesium transport (7).
Recently, Groenestege and colleagues identified a point
mutation in pro-EGF that disrupts sorting of the protein to
the basolateral membrane of distal convoluted tubule cells in
kidney nephrons (8). As a consequence, inhibition of the EGFR
by anti-EGFR antibodies as cetuximab might lead to renal Mg2+
wasting.
A previous study reported that patients with colorectal
cancers treated with cetuximab may develop a Mg wasting
syndrome with hypomagnesemia and inappropriate urinary
excretion (12).
Tejpar et al. confirmed these findings, reporting that EGFR-
targeting antibodies (cetuximab and panitumumab) may lead
to magnesium wasting in patients affected by colon cancer
(18). Another study reported a retrospective analysis of
magnesium decreasing during cetuximab treatment and, in
particular, a severe hypomagnesemia was associated with
treatment duration (19).
Our results confirm the previous findings by showing a
progressive decrease in serum magnesium concentrations in
our patients during EGFR-targeting treatment. We monitored
magnesium serum concentrations during a period of 92 days in
a homogeneous cohort of patients affected by metastatic colon
rectal cancer (all patients were treated with the same anticancer
regimen).
In the present study, hypomagnesemia G1 occurred only in
3 patients and in all of them at the last time point (92 days).
Our data show that the incidence of significant hypomagnese-
mia is less frequent than that observed in previous study by
Tejpar and colleagues, even if our observation time for
hypomagnesemia is shorter than that studied by Tejpar.
Interestingly, although the two studied populations are
different, most importantly, our population is more homoge-
neous and treated only with one anticancer regimen; the
Table 3. TTP according to the entity of
magnesium reduction
Magnesium reduction
(%)
No. patients Median TTP
(95% CI)
V10 21 3.8 (3.1-4.4)
10-20 22 5.1 (4.7-5.7)
z20 25 6.0 (4.3-9.9)
Table 4. Influence of magnesium reduction and skin toxicity on tumor response, TTP, and OS
P
Magnesium reduction
Tumor response, no. patients (%)
V20% reduction of magnesium levels 11/43 (25.6%) 0.004
>20% reduction of magnesium levels 16/25 (64.0%)
TTP (mo), median (95% CI)
V20% reduction of magnesium levels 3.90 (3.15-4.04) <0.0001
>20% reduction of magnesium levels 6.00 (5.65-6.57)
OS (mo), median (95% CI)
V20% reduction of magnesium levels 8.90 (7.697-10.103) 0.021
>20% reduction of magnesium levels 10.7 (10.045-11.355)
Skin toxicity
Tumor response, no. patients (%)
Grade 0-1-2 12/42 (28.6%) 0.033
Grade 3 15/26 (57.7%)
TTP (mo), median (95% CI)
Grade 0-1-2 4.01 (3.75-4.45) 0.002
Grade 3 6.00 (5.53-6.44)
OS (mo), median (95% CI)
Grade 0-1-2 9.70 (8.488-10.912) 0.229
Grade 3 9.89 (0.808-10.183)
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median time of onset of hypomagnesemia in the report by
Tejpar is very close to our last time point. Dissimilar eating
habits might be responsible of this discrepancy.
Finally, for the first time in the literature, we evaluated the
existence of a correlation between the occurrence of magnesium
serum level reduction and clinical response/outcome (in terms
of TTP and OS) during cetuximab treatment.
Clinical studies of cetuximab in metastatic colorectal cancer
failed to reveal an association between clinical outcome and
EGFR protein expression as measured by immunohistochem-
istry (20, 21). Furthermore, clinical responses have been shown
in patients with undetectable EGFR protein expression (22) and
somatic mutations in the EGFR tyrosine kinase domain are
associated with sensitivity to the tyrosine kinase inhibitors but
not to cetuximab (23, 24).
On the contrary, KRAS (a downstream gene of EGFR)
mutation is associated with resistance to cetuximab and a
shorter survival in EGFR-positive metastatic colorectal cancer
patients treated with this therapy. Thus, KRAS mutation status
might allow the identification of patients who are likely to
benefit from cetuximab and avoid a costly and potentially
toxic administration of this treatment in nonresponder
patients (25, 26).
Moreover, some other EGFR downstream genes seem to be
related to sensitivity to anti-EGFR–based anticancer therapy.
The overexpression of the EGFR ligands epiregulin and
amphiregulin seems to predict antitumor activity resulting
Fig. 1. Kaplan-Meier survival plots forTTP in advanced colorectal cancer treated
with cetuximab plus irinotecan according to the presence of severe acne-like rash
(A) and magnesium modifications (B).
Fig. 2. Kaplan-Meier survival plots for OS in advanced colorectal cancer treated
with cetuximab plus irinotecan according to the presence of severe acne-like rash
(A) and magnesium modifications (B).
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from cetuximab therapy (27). Moreover, Scartozzi and
colleagues showed that tumors that constitutively and aber-
rantly express nuclear factor-nB are more likely to be refractory
to cetuximab and irinotecan than those that do not show
nuclear expression of this transcriptional factor (28). Finally,
the loss of PTEN protein expression is also associated with
nonresponsiveness to cetuximab (29).
The effects of Mg2+ on microvascular endothelial cell
functions that could contribute to the regulation/deregulation
of angiogenesis are rather intricate. Therefore, the reduction of
magnesium circulating levels could justify the previous reported
reduction of vascular endothelial growth factor serum levels in
colorectal cancer patients (30, 31). Consequently, magnesium
reduction could be involved in the complex cross-talk between
EGFR pathway and angiogenesis.
In conclusion, our results confirm that cetuximab treatment
may induce a reduction of magnesium serum levels and offer
the first evidence in considering magnesium decrease as a new
predictor factor of efficacy and outcome in colorectal cancer
patients treated with cetuximab + irinotecan.
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